This company has been marked as potentially delisted and may not be actively trading. Cardiff Oncology (TROV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock TROV vs. ZIVO, IZTC, CVM, CRTX, JATT, FNCH, ALVR, CLDI, NKGN, and AIMShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include ZIVO Bioscience (ZIVO), Invizyne Technologies (IZTC), CEL-SCI (CVM), Cortexyme (CRTX), JATT Acquisition (JATT), Finch Therapeutics Group (FNCH), AlloVir (ALVR), Calidi Biotherapeutics (CLDI), NKGen Biotech (NKGN), and AIM ImmunoTech (AIM). These companies are all part of the "medical" sector. Cardiff Oncology vs. Its Competitors ZIVO Bioscience Invizyne Technologies CEL-SCI Cortexyme JATT Acquisition Finch Therapeutics Group AlloVir Calidi Biotherapeutics NKGen Biotech AIM ImmunoTech ZIVO Bioscience (NASDAQ:ZIVO) and Cardiff Oncology (NASDAQ:TROV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation. Is ZIVO or TROV more profitable? ZIVO Bioscience has a net margin of 0.00% compared to Cardiff Oncology's net margin of -3,688.31%. ZIVO Bioscience's return on equity of 0.00% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets ZIVO BioscienceN/A N/A -2,240.92% Cardiff Oncology -3,688.31%-202.00%-122.92% Which has more risk & volatility, ZIVO or TROV? ZIVO Bioscience has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Does the media favor ZIVO or TROV? In the previous week, ZIVO Bioscience had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 1 mentions for ZIVO Bioscience and 0 mentions for Cardiff Oncology. ZIVO Bioscience's average media sentiment score of 0.00 equaled Cardiff Oncology'saverage media sentiment score. Company Overall Sentiment ZIVO Bioscience Neutral Cardiff Oncology Neutral Which has better valuation and earnings, ZIVO or TROV? ZIVO Bioscience has higher earnings, but lower revenue than Cardiff Oncology. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZIVO Bioscience$15.85K4,334.76-$7.78M-$2.58-6.98Cardiff Oncology$250K102.18-$16.41M-$2.80-0.83 Do insiders and institutionals hold more shares of ZIVO or TROV? 12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 10.0% of Cardiff Oncology shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by insiders. Comparatively, 0.6% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryZIVO Bioscience beats Cardiff Oncology on 8 of the 12 factors compared between the two stocks. Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TROV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TROV vs. The Competition Export to ExcelMetricCardiff OncologyBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.55M$284.09M$5.82B$9.76BDividend YieldN/AN/A4.40%4.04%P/E Ratio-0.77N/A31.3826.05Price / Sales102.18563.89472.41122.40Price / CashN/A22.4425.7828.78Price / Book2.4710.439.526.07Net Income-$16.41M-$115.81M$3.26B$265.39M Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TROVCardiff OncologyN/A$2.32+2.7%N/A-2.9%$25.55M$250K-0.77N/AZIVOZIVO Bioscience0.2717 of 5 stars$18.04-2.4%N/A+118.2%$68.86M$15.85K-3.7010News CoverageGap UpIZTCInvizyne TechnologiesN/A$9.76+0.6%N/AN/A$61.02MN/A0.0029News CoverageCVMCEL-SCI1.3182 of 5 stars$8.47-5.0%N/A-71.8%$58.29MN/A-17.6543Positive NewsCRTXCortexymeN/A$1.67-1.2%N/A+154.3%$50.35MN/A-0.5655JATTJATT AcquisitionN/A$1.74+4.8%N/A-43.7%$30.02MN/A0.003High Trading VolumeFNCHFinch Therapeutics GroupN/A$12.50-1.6%N/A+17.2%$20.08MN/A-1.42190High Trading VolumeALVRAlloVirN/A$2.50+1.6%N/A-85.4%$12.61MN/A-0.12110Gap UpHigh Trading VolumeCLDICalidi Biotherapeutics0.736 of 5 stars$3.00-26.8%N/A-87.1%$9.08MN/A0.0038News CoverageNKGNNKGen BiotechN/A$0.13-5.4%N/A-84.6%$5.96MN/A-0.03N/AAIMAIM ImmunoTech1.1517 of 5 stars$2.51+6.4%$275.00+10,856.2%-92.7%$1.92M$121K-5.3420News CoverageGap Up Related Companies and Tools Related Companies ZIVO Competitors IZTC Competitors CVM Competitors CRTX Competitors JATT Competitors FNCH Competitors ALVR Competitors CLDI Competitors NKGN Competitors AIM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TROV) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access